Avitas Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Avitas Wealth Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57,016	Closed	-$3.31M	–	200
2023 Q3	$3.31M	Sell	57,016 -222	-0.4%	-$13.6K	0.63%	38
2023 Q2	$3.66M	Buy	57,238 +336	+0.6%	+$22.5K	0.66%	42
2023 Q1	$3.94M	Sell	56,902 -583	-1%	-$41.1K	0.77%	34
2022 Q4	$4.14M	Sell	57,485 -589	-1%	-$44.4K	0.87%	35
2022 Q3	$4.13M	Buy	58,074 +478	+0.8%	+$34.7K	0.95%	27
2022 Q2	$4.43M	Buy	57,596 +845	+1%	+$64.4K	0.97%	26
2022 Q1	$4.14M	Buy	+56,751	New	+$3.81M	0.75%	32
2021 Q4	–	Sell	-35,802	Closed	-$2.12M	–	179
2021 Q3	$2.12M	Sell	35,802 -29,740	-45%	-$1.96M	0.39%	100
2021 Q2	$4.38M	Buy	65,542 +2,730	+4%	+$178K	0.78%	42
2021 Q1	$3.96M	Buy	+62,812	New	+$3.91M	0.78%	41
2018 Q4	–	Sell	-52,169	Closed	-$3.24M	–	150
2018 Q3	$3.24M	Buy	52,169 +2,018	+4%	+$120K	0.92%	42
2018 Q2	$2.77M	Buy	+50,151	New	+$2.71M	0.86%	50

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Avitas Wealth Management's BMY Position: Q4 2023 in Review

Avitas Wealth Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 57,016 shares — an estimated $3.31M sold.

Avitas Wealth Management first reported a position in BMY in Q2 2018 and held it in 12 quarters. The position peaked at $4.43M in Q2 2022. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Avitas Wealth Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Avitas Wealth Management sold 57,016 Bristol-Myers Squibb shares in Q4 2023, an estimated $3.31M.
Avitas Wealth Management first reported a position in Bristol-Myers Squibb in Q2 2018 and held it in 12 quarters.
Avitas Wealth Management's Bristol-Myers Squibb position peaked at $4.43M in Q2 2022.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Avitas Wealth Management's 13F filing for Q4 2023, filed 24 Jan 2024.